These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2937534)

  • 1. High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase II study.
    Kjaer M; Frederiksen PL
    Cancer Treat Rep; 1986 Mar; 70(3):431-2. PubMed ID: 2937534
    [No Abstract]   [Full Text] [Related]  

  • 2. [Clinovir treatment of adenocarcinoma of the uterus with lung metastases].
    Stertmann WA; Hocke M; Röttger P
    MMW Munch Med Wochenschr; 1983 Jul; 125(29-30):685-6. PubMed ID: 6225946
    [No Abstract]   [Full Text] [Related]  

  • 3. Endocrinological effects of treatment with high doses of medroxyprogesterone acetate in patients with renal or prostatic adenocarcinoma.
    Tomic R; Ljungberg B; Damber JE
    Scand J Urol Nephrol Suppl; 1988; 110():185-7. PubMed ID: 2973122
    [No Abstract]   [Full Text] [Related]  

  • 4. [The treatment of metastasizing hypernephroid (renal cell) carcinoma with medroxyprogesterone acetate (Clinovir) (author's transl].
    von Lieven H; Hahn D
    MMW Munch Med Wochenschr; 1977 Aug; 119(34):1089-92. PubMed ID: 408657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemo-hormonal therapy for metastatic renal cell carcinoma with adriamycin, hydroxyurea, vinblastine, and medroxyprogesterone acetate.
    Katakkar SB; Franks CR
    Cancer Treat Rep; 1978 Sep; 62(9):1379-80. PubMed ID: 688282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Experiences with Depo-Provera (medroxyprogesterone) in the treatment of kidney tumors].
    Balogh F; Romics I
    Z Urol Nephrol; 1987 Aug; 80(8):449-53. PubMed ID: 2961162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced adenocarcinoma of the kidney: therapy with lomustine, vinblastine, hydroxyurea, and medroxyprogesterone acetate and regression analysis of factors relating to survival.
    Brubaker LH; Troner MB; Birch R
    Cancer Treat Rep; 1983; 67(7-8):741-2. PubMed ID: 6223695
    [No Abstract]   [Full Text] [Related]  

  • 8. High-dose medroxyprogesterone acetate (MPA) in advanced chemotherapy-resistant ovarian carcinoma: a phase II study.
    Aabo K; Pedersen AG; Haid I; Dombernowsky P
    Cancer Treat Rep; 1982 Feb; 66(2):407-8. PubMed ID: 6459846
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II study of oral medroxyprogesterone acetate in advanced germ cell tumors.
    Cavalli F; Klepp O; Hansen H; Rozencweig M
    Cancer Treat Rep; 1983 Oct; 67(10):953-4. PubMed ID: 6313188
    [No Abstract]   [Full Text] [Related]  

  • 10. [the oral use of a progestational hormone (Provera 100) as an adjuvant in therapy of adenocarcinoma of the kidney. Preliminary report].
    Liberti M; Di Silverio F; Concolino G; Tenaglia R; Marocchi A
    Minerva Urol; 1980; 32(3):175-8. PubMed ID: 7432332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma.
    Kjaer M
    Cancer Treat Rev; 1988 Sep; 15(3):195-209. PubMed ID: 2974757
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II study of medroxyprogesterone acetate with tamoxifen in advanced renal cell cancer.
    Fuks JZ; Aisner J; Van Echo DA; Wiernik PH
    Cancer Treat Rep; 1982 Sep; 66(9):1773-4. PubMed ID: 7116354
    [No Abstract]   [Full Text] [Related]  

  • 13. [A case of marked effectiveness using medroxyprogesterone acetate (MPA) in lung metastases of cancer of the uterine body].
    Takeda M; Kubo K; Fukushima M; Hirayama J; Sekiguchi M
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2113-7. PubMed ID: 2145808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Yoshi 864 plus medroxyprogesterone acetate in adenocarcinoma of the kidney: A Southwest Oncology Group Study.
    Altman SJ; Stephens RL; Bonnet JD
    Cancer Treat Rep; 1982 Sep; 66(9):1781-2. PubMed ID: 6288240
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
    Sasagawa I; Satomi S; Umeda K; Katayama T
    Hinyokika Kiyo; 1989 Apr; 35(4):603-8. PubMed ID: 2525316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
    Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of medroxyprogesterone acetate and doxorubicin on sublines of 13762 mammary adenocarcinoma in rats.
    Formelli F; Zaccheo T; Casazza AM; Bellini O; Di Marco A
    Eur J Cancer Clin Oncol; 1981 Nov; 17(11):1211-21. PubMed ID: 6460631
    [No Abstract]   [Full Text] [Related]  

  • 18. [Mistletoe therapy of metastasizing renal cancer. A phase II study].
    Kjaer M
    Ugeskr Laeger; 1988 Aug; 150(32):1923-8. PubMed ID: 3413875
    [No Abstract]   [Full Text] [Related]  

  • 19. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
    Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
    J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Progestins in combined treatment of endometrial cancer].
    Voznyĭ EK; Titova VA
    Sov Med; 1990; (9):102-7. PubMed ID: 2148437
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.